ArticleFrontiers in cardiovascular medicine2026
Continuous assessment and research on enhanced blood pressure control - CareBP study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypertension and its pre-stages are the leading cardiovascular risk factors worldwide, why awareness and prevention are highly relevant. Novel blood pressure devices can provide a broader picture at an earlier stage and enable an assessment of elevated values. The aim of this pilot study was to provide pharmacist-led support for the use, analysis and communication of a 14-day-cuffless blood pressure monitoring in potential hypertensive adults. Methods: For this pilot study ten adults were enrolled, who had elevated blood pressure values (>130 mmHg systolic and/ or >85 mmHg diastolic) in the past but no current cardiovascular diagnosis or medication. Participants were guided to use a cuffless blood pressure device (Aktiia/ Hilo bracelet) for 14 full days. The blood pressure profiles were analyzed with a previously developed blood pressure model and compared with profiles of normotensive adults. Results: The blood pressure profiles demonstrated individual blood pressure patterns in all participants. Six of ten participants were above the recommended 24-hour-threshold of 135/85 mmHg, one was at the threshold and three were under the threshold during the study period. Besides the blood pressure levels, there were differences regarding variability, night-dips and number of measurements. Compared to normotensives, base blood pressure was higher in potential hypertensives. Finally, the results were communicated to the participants for further discussion with other healthcare professionals. Discussion: The combination of a cuffless device, model-based analysis and pharmacist support represents a promising translational approach for individualized blood pressure monitoring. The results of the CareBP study show the extended value of 14 days of individual blood pressure monitoring and underline the relevance of this approach for cardiovascular disease prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.